Published in:
01-03-2016 | Hepatobiliary Tumors
Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study
Authors:
Chia-Yang Hsu, MD, MPH, Po-Hong Liu, MD, Cheng-Yuan Hsia, MD, Yun-Hsuan Lee, MD, Teddy S. Nagaria, MD, PhD, Rheun-Chuan Lee, MD, Han-Chieh Lin, MD, Teh-Ia Huo, MD
Published in:
Annals of Surgical Oncology
|
Issue 3/2016
Login to get access
Abstract
Background
The clinical outcomes in hepatocellular carcinoma (HCC) patients receiving surgical resection (SR) or transarterial chemoembolization (TACE) are diverse. This study aimed to develop a nomogram to predict individualized survival risk in patients with HCC beyond the Milan criteria undergoing aggressive treatments (SR and TACE).
Methods
A total of 1009 patients were enrolled in the study and randomly grouped into derivation (n = 505) and validation sets (n = 504). The multivariate Cox proportional hazards model was used to select significant prognostic predictors from the derivation set to generate the nomogram. The performance of the nomogram was evaluated by discrimination (concordance index) and calibration tests.
Results
Serum albumin <3.8 g/dL, α-fetoprotein ≥400 ng/mL, TACE, vascular invasion, multiple tumors, and tumor volume ≥200 cm3 were associated with poor survival in the multivariate Cox model (all p < 0.05). A nomogram with a scale of 0–47 was developed with these six variables, and the predicted survival rates at 1 and 3 years were calculated. The derivation set with bootstrapping (B = 100) had a good concordance index of 0.694 [95 % confidence interval (CI) 0.68–0.708]. Discrimination test in the validation set provided a concordance index of 0.71 (95 % CI 0.697–0.722), and the calibration plots well-matched the 45-degree line for 1- and 3-year survival prediction. The respective survival for patients undergoing SR or TACE could be predicted based on the nomogram across different risk scores.
Conclusions
This easy-to-use nomogram may accurately predict survival at 1 and 3 years for individual HCC patients beyond the Milan criteria, and provide quantitative survival advantage of SR over TACE.